For early detection of colorectal (colon) cancer, statutory health insurance in Germany offers a fecal occult blood test free of charge to all insured persons starting at 50 years of age. In addition, those 55 or older are entitled to an endoscopic examination of the colon (colonoscopy). Colonoscopy identifies precancerous lesions with a high level of exactitude. Nevertheless, only about 20-30 percent of those eligible actually take advantage of the screening examination. "Therefore, fecal occult blood tests are important, because they help us reach more people. People are much more willing to have a simple laboratory test. Hence it is all the more important for these tests to provide valuable results," says Professor Hermann Brenner from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).
The test covered by health insurance is based on the detection of enzymatic activity in fecal occult blood (a "stool guaiac test"). For several years now, immunological testing methods using antibodies to detect hemoglobin in stool samples have also been available. These tests are regarded as more sensitive; i.e., they are believed to detect more tissue abnormalities. Until now, however, the two methods have only been compared in a few small-scale studies.
Hermann Brenner and his coworker Sha Tao have now directly compared the two methods in a large-scale study for the first time. 2,235 participants who underwent colon cancer screening colonoscopies between 2005 and 2009 provided stool samples immediately prior to the examination. These were tested for occult blood using both methods. Subsequently, the DKFZ researchers analyzed the test results by comparing them with the results from colonoscopies.
The enzyme-based test detected one third of all colon cancer cases, about nine percent of advanced precancerous lesions (adenomas), and about five percent of early precancerous lesions. The specificity was slightly over 95 percent: In 95 out of 100 participants with negative test results, no tissue abnormalities were found in the subsequent colonoscopy.
However, the three immunological tests* that were used detected about twice as many cancer cases (60.0, 53.3 and 73.3 percent) and about three times as many advanced precancerous lesions, with a specificity that was a little higher than enzymatic testing.
Only one third (31 percent) of all positive results from enzymatic testing were in fact the result of a tissue abnormality. By contrast, colonoscopy confirmed the presence of an abnormality in about two thirds (57 to 68 percent) of positive results obtained by immunological testing. "Immunological tests can thus help encourage people with a positive finding to undertake a colonoscopy afterwards, meaning that those individuals who actually have precancerous lesions would likely participate in colonoscopy screening," explains Brenner.
The enzymatic test only provides a positive or negative result, whereas the immunological test quantifies hemoglobin levels. The researchers therefore had to make the results comparable by defining threshold values for the immunological tests such that both methods delivered the same number of positive results.
"For the first time we have shown by direct comparison that the diagnostic performance of immunological stool tests is significantly higher than that of the enzymatic test at the same rate of positive results," says Hermann Brenner. He hopes that his research will provide a convincing argument to health-care policy makers. "Tests for occult blood in the stool will continue to be an important part of colon cancer screening. We therefore recommend including immunological tests in cancer screening programs in Germany. Many more people would thus benefit by obtaining a life-saving clue pointing to a hidden case of cancer."
In a number of European countries that offer cancer screening programs, immunological tests have already become the standard. Besides higher sensitivity, they offer further practical advantages: They can be more easily automated, and participants do not have to avoid certain types of food prior to the test, because the antibodies react specifically to human hemoglobin. Brenner is convinced that the slightly higher costs of immunological testing will fall once the tests can be produced on a large scale.
Hermann Brenner and Sha Tao: Superior diagnostic performance of fecal immunochemical tests for hemoglobin in a head-to-head comparison with guaiac based fecal occult blood test among 2235 participants of screening colonoscopy. European Journal of Cancer 2013, http://dx.doi.org/10.1016/j.ejca.2013.04.023
* Tests studied:
HemOccult, Beckman Coulter, Krefeld, Germany
RIDASCREEN® Haemoglobin, Biopharm, Darmstadt, Germany
RIDASCREEN® Haemo-/Haptoglobin-Complex, Biopharm, Darmstadt, Germany
OC Sensor, Eiken Chemicals, Tokyo, Japan
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.
European Journal of Cancer